OS Therapies Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OS Therapies Inc. on March 31, 2026. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Grasonville, Maryland. Its common stock trades under the symbol OSTX on the NYSE American.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than periodic financial performance.
Material Changes and Events
- Prospectus Supplement Filed: On March 31, 2026, the Company filed a prospectus supplement as part of its previously effective Form S-3 registration statement (File No. 333-289443).
- Share Resale: The supplement covers the resale from time to time of up to 10,529,417 shares of the Company's common stock by selling stockholders.
- Legal Opinion: The 8-K includes the legal opinion of counsel, Olshan Frome Wolosky LLP, regarding the legality of the shares (Exhibit 5.1).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, or contingencies beyond the standard disclosure of the share resale event.
Investor Verification Checklist
- Verify the identity of the selling stockholders referenced in the Prospectus Supplement.
- Review the full text of the Prospectus Supplement to understand the terms of the share resale.
- Confirm the impact of the potential 10,529,417 share resale on market dilution.
- Examine Exhibit 5.1 for the specific legal opinion regarding the legality of the shares.